Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis : A case report
© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd..
Patients with acute myeloid leukemia (AML) who have comorbidities have limited treatment options, thereby resulting in poor prognosis. Venetoclax, a specific B-cell lymphoma-2 inhibitor, has recently been approved for AML in combination with hypomethylating agents; however, only one report has described its use in patients undergoing dialysis. Herein, we report the effectiveness of combined venetoclax and azacitidine in a 73-year-old man with AML undergoing dialysis and who was ineligible for standard therapies. The safety of venetoclax and azacitidine in patients undergoing dialysis has been reported, and their combination may be a feasible option for patients with AML undergoing dialysis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
EJHaem - 4(2023), 3 vom: 24. Aug., Seite 841-843 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Akagi, Yuina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute myeloid leukemia |
|---|
| Anmerkungen: |
Date Revised 23.08.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/jha2.732 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361005873 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361005873 | ||
| 003 | DE-627 | ||
| 005 | 20231226084229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jha2.732 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM361005873 | ||
| 035 | |a (NLM)37601888 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Akagi, Yuina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis |b A case report |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.08.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Patients with acute myeloid leukemia (AML) who have comorbidities have limited treatment options, thereby resulting in poor prognosis. Venetoclax, a specific B-cell lymphoma-2 inhibitor, has recently been approved for AML in combination with hypomethylating agents; however, only one report has described its use in patients undergoing dialysis. Herein, we report the effectiveness of combined venetoclax and azacitidine in a 73-year-old man with AML undergoing dialysis and who was ineligible for standard therapies. The safety of venetoclax and azacitidine in patients undergoing dialysis has been reported, and their combination may be a feasible option for patients with AML undergoing dialysis | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a acute myeloid leukemia | |
| 650 | 4 | |a azacitidine | |
| 650 | 4 | |a dialysis | |
| 650 | 4 | |a venetoclax | |
| 700 | 1 | |a Yamashita, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kosako, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Furuya, Yoshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Hosoi, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Mushino, Toshiki |e verfasserin |4 aut | |
| 700 | 1 | |a Murata, Shogo |e verfasserin |4 aut | |
| 700 | 1 | |a Nishikawa, Akinori |e verfasserin |4 aut | |
| 700 | 1 | |a Tamura, Shinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Nakao, Taisei |e verfasserin |4 aut | |
| 700 | 1 | |a Sonoki, Takashi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EJHaem |d 2020 |g 4(2023), 3 vom: 24. Aug., Seite 841-843 |w (DE-627)NLM314118454 |x 2688-6146 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2023 |g number:3 |g day:24 |g month:08 |g pages:841-843 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jha2.732 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2023 |e 3 |b 24 |c 08 |h 841-843 | ||